BREAKING
Eli Lilly and Company (LLY) to acquire Orna Therapeutics 9 minutes ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 59 minutes ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 2 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 5 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 5 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 5 hours ago Johnson Outdoors Hooks 31% Revenue Gain, Operating Loss Narrows 6 hours ago Innovation and E-Commerce at the Core of Johnson Outdoors’ 2026 Roadmap 6 hours ago Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 3 days ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 3 days ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 9 minutes ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 59 minutes ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 2 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 5 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 5 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 5 hours ago Johnson Outdoors Hooks 31% Revenue Gain, Operating Loss Narrows 6 hours ago Innovation and E-Commerce at the Core of Johnson Outdoors’ 2026 Roadmap 6 hours ago Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 3 days ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 3 days ago
ADVERTISEMENT
AlphaGraphs

Key highlights from Abbott (ABT) Q3 2022 earnings results

Abbott (NYSE: ABT) reported third quarter 2022 earnings results today. Sales decreased 4.7% year-over-year to $10.4 billion. On an organic basis, sales increased 1.3%. Net earnings declined 31.7% to $1.4 billion while EPS fell 30.8% to $0.81. Adjusted EPS dropped 18% to $1.15. For FY2022, Abbott expects adjusted EPS to be $5.17-5.23. Prior performance

$ABT October 19, 2022 1 min read

Abbott (NYSE: ABT) reported third quarter 2022 earnings results today.

Sales decreased 4.7% year-over-year to $10.4 billion. On an organic basis, sales increased 1.3%.

Net earnings declined 31.7% to $1.4 billion while EPS fell 30.8% to $0.81. Adjusted EPS dropped 18% to $1.15.

For FY2022, Abbott expects adjusted EPS to be $5.17-5.23.

Prior performance

Abbott Laboratories Q2 2022 Earnings Infographic
ADVERTISEMENT